Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04066894
Other study ID # 2016-0754
Secondary ID NCI-2019-0264920
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 12, 2019
Est. completion date September 1, 2022

Study information

Verified date July 2023
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to nearby tissues or lymph nodes, or other pelvic cancer. Sacral nerve stimulation is a permanent implant that may improve bowel functions by stimulating the nerves that control the muscles related to bowel function.


Description:

PRIMARY OBJECTIVES: I. To investigate the efficacy of sacral nerve stimulator placement in patients with fecal incontinence (FI) or low anterior resection syndrome (LARS) who have previously undergone chemoradiation treatment (XRT) and/or a restorative partial or complete proctectomy with colorectal or coloanal anastomosis for cancer treatment as per standard of care (restorative surgery cohort). II. To evaluate the feasibility of sacral nerve stimulator placement in patients with fecal incontinence (FI) or other defecatory dysfunction who have received pelvic radiation treatment without undergoing rectal or other pelvic surgery as per standard of cancer care (radiation only cohort). SECONDARY OBJECTIVES: I. To evaluate the effectiveness of sacral nerve stimulation (SNS) as measured by validated questionnaires in patients with FI or LARS within both patient cohorts. II. To evaluate pelvic floor and sphincter physiology using anorectal manometry (ARM) before and after SNS in patients with FI or LARS within both patient cohorts. III. To assess potential impact of SNS on urinary incontinence measuring a post-void urinary bladder residual and validated urinary symptom questionnaires in both patient cohorts. IV. To assess efficacy of SNS on long-term bowel dysfunction at 1 and 3 years post battery implantation as measured by validated questionnaires for both patient cohorts. OUTLINE: Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads. After completion of study, patients are followed up at 1 month, 1 year, and 3 years.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Cohort 1: Patients with pathologically proven diagnosis of primary rectal cancer - Cohort 1: Patients who have previously undergone surgical resection and anastomosis (restorative) with curative intent treatment with or without chemoradiation - Cohort 1: Patients treated with restorative surgical resection without radiation - Cohort 1: Patients with any T-stage or N-stage rectal cancer that underwent treatment with radiation and restorative surgery - Cohort 1: Patients with self-reported FI or LARS - Cohort 1: Patients must be at least 18 years old and be able to speak and understand English - Cohort 1: Patients must be willing to and able to sign an approved informed consent document - Cohort 1: Patients must be >= 24 months post-resection of rectal cancer - Cohort 1: Patients must have failed prior conservative measures such as Metamucil and motility medications and already been assessed and treated in a pelvic floor rehabilitation program (biofeedback) designed to treat FI and LARS, and continue to experience significant defecatory dysfunction, allowable per principal investigator (PI) discretion - Cohort 1: Patients must be willing and able to complete Patient Reported Outcomes Questionnaires for before device placement, during the testing phase following lead placement, and after implantation of the battery - Cohort 1: Patients must be willing and able to undergo elective ARM testing to objectively measure pelvic floor function - Cohort 1: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM - Cohort 2: Patients with pathologically proven malignancy of the pelvis, other than rectal cancer (e.g. prostate, bladder, anus, vagina, vulva, cervix, uterus, or ovary) - Cohort 2: Patients treated with standard of care radiation therapies without surgical resection - Cohort 2: Patients with self-reported FI or other defecatory dysfunction - Cohort 2: Patients must be at least 18 years old and be able to speak and understand English - Cohort 2: Patients must be willing to and able to sign an approved informed consent document - Cohort 2: Patients must be >= 18 months post-pelvic chemoradiation - Cohort 2: Patients must have already been assessed and treated in a pelvic floor rehabilitation program design to treat FI or other defecatory dysfunction and continue to experience significant defecatory dysfunction - Cohort 2: Patients must be willing and able to complete Patient Reported Outcomes (PROs) and bowel and bladder diaries (Medtronic) at multiple times during the study - Cohort 2: Patients must be willing and able to undergo elective ARM testing to measure pelvic floor function - Cohort 2: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM Exclusion Criteria: - Cohort 1: Patients with co-morbid illnesses or concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Cohort 1: Any diverting bowel ostomy at the time of consent to this study - Cohort 1: Patients with an absolute neutrophil count (ANC) < 1.7 within 30 days of consent - Cohort 1: Patients with an international normalized rate (INR) > 1.3 within 30 days of consent - Cohort 1: Patients with a platelet count < 50 K within 30 days of consent - Cohort 1: Patients currently being treated with chemotherapy or within preceding 30 days at the time consent - Cohort 1: Patients previously treated with a SNS for urinary or FI - Cohort 1: Patients who were documented to have an anastomotic leak following their restorative surgical resection - Cohort 1: Patients with an Eastern Cooperative Oncology Group (ECOG) performance status > 2 at the time of consent - Cohort 1: Patients with an active infection requiring systemic therapy at the time of consent - Cohort 1: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure - Cohort 2: Co-morbid illnesses or other concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Cohort 2: Patients with an ANC < 1.7 within 30 days of consent - Cohort 2: Patients with an INR > 1.3 within 30 days of consent - Cohort 2: Patients with a platelet count < 50 K, within 30 days of consent - Cohort 2: Patients currently being treated with chemotherapy or within the preceding 30 days at the time of consent - Cohort 2: Patients previously treated with a sacral nerve stimulator for urinary or fecal incontinence - Cohort 2: Patients with an ECOG performance status > 2 at the time of consent - Cohort 2: Patients with an active infection requiring systemic therapy at the time of consent - Cohort 2: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure - Cohort 2: Patients with an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study

Study Design


Related Conditions & MeSH terms

  • Anus Neoplasms
  • Fecal Incontinence
  • Low Anterior Resection Syndrome
  • Malignant Anal Neoplasm
  • Malignant Bladder Neoplasm
  • Malignant Cervical Neoplasm
  • Malignant Ovarian Neoplasm
  • Malignant Pelvic Neoplasm
  • Malignant Prostate Neoplasm
  • Malignant Uterine Neoplasm
  • Malignant Vaginal Neoplasm
  • Malignant Vulvar Neoplasm
  • Neoplasms
  • Ovarian Neoplasms
  • Pelvic Neoplasms
  • Prostatic Neoplasms
  • Rectal Carcinoma
  • Syndrome
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms
  • Vaginal Neoplasms
  • Vulvar Neoplasms

Intervention

Procedure:
Explantation
Undergo lead removal
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Device:
Sacral Nerve Stimulator
Undergo sacral nerve stimulator implantation
Sacral Nerve Stimulator Battery
Undergo sacral nerve stimulator battery implantation
Procedure:
Therapeutic Conventional Surgery
Undergo sacral nerve stimulator implantation

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas
United States MD Anderson in Sugar Land Sugar Land Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sacral Nerve Stimulation (SNS) Success SNS success will be measured as a patient having the battery implanted at visit 3. Patients who do not have the SNS placed, for any reason other than insurance coverage issues, will count as not having a success. Fecal incontinence will be measured by the physician as the total number of gas, mucus, liquid stool, and solid stool accidental leakage events reported in the bowel diaries. Improvement will be determined by the physician based on bowel diary comparisons recorded before SNS lead placement at visit 1 to after lead placement at visit 2. The proportion of patients who experience SNS success will be reported with a 90% credible interval using a beta (1,1) Up to visit 3
Secondary Fecal Incontinence Severity Index Questionnaire Summary Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Fecal Incontinence Quality of Life Questionnaire Summary Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Euroqol-5 Dimensions-5 Levels (EQ-5D-5L) Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary International Consultation on Incontinence Society - Female Lower Urinary Tract Symptoms Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Memorial Sloan Kettering Cancer Center Bowel Function Questionnaire (BFQ) Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Low Anterior Resection Syndrome Score BFQ Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Cleveland Clinic Incontinence Score Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
Secondary Impact of SNS on Bowel Dysfunction Will be measured using bowel diaries. Up to 30 days (visit 2)
Secondary Impact of SNS on Urinary Incontinence Will be measured using bladder diaries and a post-void urinary bladder residual and validated urinary symptom questionnaire. Up to 30 days (visit 2)
Secondary European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29 Will be reported descriptively with graphs or tabulations for categorical survey outcomes. Up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04087421 - Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome Phase 3
Recruiting NCT03828318 - Impact of a Patient-Centered Program for Low Anterior Resection Syndrome A Multicenter Randomized Controlled Trial N/A
Recruiting NCT04040842 - International Low Anterior Resection Score Evaluation
Recruiting NCT04023448 - The Effect of Different Reconstruction Methods on Anterior Resection Syndrome N/A
Not yet recruiting NCT06424522 - A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients Early Phase 1
Completed NCT05605600 - Translation of the International Consensus Definition of LARS Into a Bowl Dysfunction Severity Scoring Tool (New LARS Score)
Completed NCT05016583 - Paula Method of Exercises in Patients With LARS Syndrome N/A
Active, not recruiting NCT05042700 - The Effect of Melatonin in Patients With Low Anterior Resection Syndrome Phase 2
Recruiting NCT04612569 - Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
Completed NCT04896879 - Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals Regarding LARS
Recruiting NCT06162143 - Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome
Withdrawn NCT03257332 - Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
Completed NCT03916549 - Acupuncture in Low Anterior Resection Syndrome Treatment Phase 1
Completed NCT05020132 - Bowel Dysfunction After Rectal Cancer Treatment
Completed NCT03598231 - Effectiveness of Sacral Neuromodulation in Low Anterior Resection Syndrome N/A
Recruiting NCT05420870 - Effect of Exercise on Bowel Function in Colorectal Cancer Survivors N/A
Active, not recruiting NCT05319054 - Pathway of Low Anterior Resection Syndrome Relief After Surgery: a Feasibility Study N/A
Completed NCT01589471 - The Value of Botox-A for Management of Low Anterior Resection Syndrome Phase 2
Completed NCT03215017 - Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery N/A
Completed NCT05129215 - Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)

External Links